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Abstract
Introduction: Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system.
Immunological studies suggest that it is a T-cell mediated autoimmune disease, although an MS-specific target
antigen for autoimmunity has so far not been identified. Models of experimental autoimmune encephalomyelitis in
part reproduce features of MS, but none of the models so far covers the entire spectrum of pathology and
immunology. Autoimmune disease of the nervous system has occasionally been observed in humans after active
sensitization with brain tissue or brain cells, giving rise to acute demyelinating polyradiculoneuritis, acute
disseminated encephalomyelitis and in rare cases reflecting an inflammatory demyelinating condition similar to
acute multiple sclerosis. In this study we analyzed in detail the immunopathology in archival autopsy tissue of a
patient who died with an MS like disease after repeated exposure to subcutaneous injections of lyophilized brain cells.
Results: The pathology of this patient fulfilled all pathological diagnostic criteria of MS. Demyelination and tissue
injury was associated with antibody (IgM) deposition at active lesion sites and complement activation. Major
differences to classical EAE models were seen in the composition of inflammatory infiltrates, being dominated by
B-cells, infiltration of IgM positive plasma cells, profound infiltration of the tissue by CD8+ T-lymphocytes and a nearly
complete absence of CD4+ T-cells.
Conclusions: Our study shows that auto-sensitization of humans with brain tissue can induce a disease, which closely
reflects the pathology of MS, but that the mechanisms leading to demyelination and tissue injury differ from those,
generally implicated in the pathophysiology of MS through studies in experimental autoimmune encephalomyelitis.
Keywords: Multiple sclerosis, Experimental autoimmune encephalomyelitis, Inflammation, Demyelination,
Neurodegeneration
Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease
of the central nervous system, which leads to plaque like
primary demyelination in the white and grey matter and
focal as well as diffuse neurodegeneration [33]. Immuno-
logical studies suggest that autoimmunity against nervous
system antigens plays a major role in its pathogenesis, al-
though so far no MS-specific autoimmune reaction has
been identified [24]. Auto-sensitization of rodents and
primates with brain tissue, myelin or with brain proteins,
induces experimental autoimmune encephalomyelitis
(EAE), which is generally regarded as the most suitable
animal model for MS. [18] However, EAE pathology only
incompletely mimics that seen in MS, and it is currently
unclear, whether the differences are due to the genetic
background or the environmental exposure between
animals and humans or whether there are more funda-
mental differences in pathogenesis. A detailed analysis of
the immunopathology of autoimmune encephalomyelitis
in humans could fill this gap of knowledge.
Autoimmune disease in humans after active sensitization
with brain tissue is a rare event. In a detailed epidemio-
logical meta-analysis, based on more than 100.000 individ-
uals exposed to brain tissue containing rabies vaccine, an
incidence of neuroparalytic autoimmune complications has
been described as 0.3 to 1 out of 1000. The incidence was
higher in adults compared to children and individuals with
Caucasian genetic background were more frequently af-
fected compared to others. Furthermore, the incidence was
dependent upon the preparation of the vaccine [50]. Similar
autoimmune complications have been observed, following
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treatment of patients with fresh or lyophilized brain cells,
which was used in alternative medicine in the first half of
the XXth century [7, 46]. Most recently, neurological
complications have been described in workers of a slaugh-
ter house, who were chronically exposed to an aerosole of
brain tissue at their working place [31]. Inflammatory poly-
radiculoneurits was seen in 60 to 70 % of patients, while
the rest presented with a disease affecting the central ner-
vous system, mainly reflecting acute disseminated enceph-
alomyelitis or transverse myelitis [50]. Considering the
similarity of these diseases with autoimmune encephalomy-
elitis or neuritis in rodents, it is likely that these disorders
are mediated by CD4+ autoreactive T-cells [2]. In rare cases,
however, an inflammatory demyelinating phenotype was
observed resembling acute MS. [46, 54] A detailed patho-
logical analysis of such cases with inflammatory demyelin-
ating disease, using new technology, which have been
developed for the immunopathological characterization of
MS lesions, could provide answers, to what extent the
spectrum of brain alterations in MS patients may be repro-
duced in a defined human brain autoimmune disease and
about immune mechanisms, which are associated with the
demyelinating disease phenotype.
In this study we retrieved one of these cases from the
pathology archive of the Institute of Neurology of the
Medical University of Vienna ([46]; the only case for
which archival pathological material was still available
after international search) and compared its pathology in
detail with that, defined in recent years in MS patients
[33, 36]. In addition, we compared the changes in this
case with those seen in EAE in primates (marmosets,
[26, 27]) and in the commonly used chronic mouse
model, induced by sensitization of C57B6 mice by
active sensitization with myelin oligodendrocyte glyco-
protein [18, 44]. The study was approved by the local
Ethical Commission of the Medical University of
Vienna (EK. Nr. 097/01/2015).
Material and methods
Detailed clinical information of the disease course of the
patient with demyelinating human autoimmune enceph-
alitis (HAE) has been provided before [46]. In short a
51-year-old male patient presented with a mild slowly
progressive hemi-Parkinson syndrome, starting 4 years
before his death. Due to the lack of other therapeutic op-
tions the patient was treated over a period of 17 months
with 7 injections of lyophilized calf brain cells (derived from
cortex, thalamus, hypothalamus, and striatum) and placenta
cells (0.02 g dry weight in 6 to 8 ml of physiological saline)
at two to four month intervals. The first 6 injections were
well tolerated. Twenty two days after the seventh injection
the patient developed progressive right-sided hemiparesis.
This was followed by rapid deterioration of the neurological
status, leading to paraparesis, spasticity of the lower
extremities, positive Babinski reflex, and tremor, and finally
progressed to a comatous state. Seven weeks after onset of
the neurological disease the patient died due to cardio-
respiratory failure. Brain autopsy revealed large bilateral
periventricular lesions together with multiple small focal
peri-venous lesions in the cerebral white matter. Histo-
logical analysis showed active inflammatory demyelinating
lesions in the cerebral white matter and some small inflam-
matory lesions in the cerebellum, brain stem, and spinal
cord. In addition, neuronal loss and the presence of some
neurons with Lewy body inclusions were seen in the right
substantia nigra [46].
The comparison is based on archival autopsy material
of MS cases (including acute MS, relapsing MS and
primary or secondary progressive MS; [14, 17]), of brain
samples of EAE in marmosets (induced by active
sensitization with recombinant MOG; [26, 27]) and of
chronic mouse EAE (induced by active sensitization with
MOG35–55; [18, 44]), all contained in the archive of the
Center for Brain Research.
Pathological analysis
For detailed pathological analysis of the HAE case, one
hemispheric paraffin embedded block through the mid
thalamus was available (Fig. 1). Hemispheric sections
were stained with hematoxylin eosin, Luxol fast blue
myelin stain, Bielschowsky silver impregnation for axons,
and with the modified Turnbull reaction for iron.
Immunocytochemistry was in part performed on the en-
tire hemispheric section or, alternatively, in dissected
hemispheric sections, containing the lesions, the normal
appearing white matter and the cerebral cortex.
Immunocytochemistry was performed on de-paraffinized
sections using the primary antibodies listed in Table 1. This
table also contains information on methods of antigen
retrieval. Visualization of bound primary antibodies was
done with a biotin avidin technique ([13], Table 1). In situ
hybridization for proteolipid protein mRNA was performed
according to Breitschopf et al. [8] and TUNEL staining
according to Gold et al. [19]. To determine the proliferation
rate of T-cells and B-cells, the sections were first stained for
proliferating cell nuclear antigen (PCNA) using an alkaline
phosphatase technique followed by the respective markers
CD3 and CD20, visualized with a biotin-avidin-peroxidase
method. In situ hybridization for Epstein Barr Virus (EBER)
was performed using the EBER pNA detection kit (DAKO
Y5200), including an EBV+ cerebral lymphoma as a positive
control.
Quantitative analysis of axonal density was performed
in the microscope at a magnification of 20x in sections
stained for phosphorylated neurofilaments. The number
of axons, crossing a line of 2 mm were determined by
manual counting at three sites of the lesions and the
normal appearing white matter. A similar approach was
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Fig. 1 Basic Pathology of HAE: a: Topographical distribution of demyelinated lesions in the brain shows the prominent periventricular
demyelination with peri-venous extensions (Dawson Fingers) and demyelinated plaques in the cortex and the deep grey matter nuclei; green:
white matter lesions, red: cortical and hippocampal lesions, blue: lesions in thalamus and basal ganglia; the blue dots in the meninges show the
location of prominent meningeal inflammatory infiltrates; b: Sections stained with luxol fast blue depicts the demyelinated lesions in the white
matter; c: Immunocytochemistry for CD68 shows the accumulation of macrophages at the edge of active white matter lesions; d: Double staining
for proteolipid (PLP) protein (red) and mRNA (black) reveals loss of oligodendrocytes within the lesion and the presence of numerous macrophages
with PLP degradation products at the lesion edge; e: In sections stained for phosphorylated neurofilament only a mild to moderate reduction of axonal
density is seen in the lesions; the insert shows a neuron in the substantia nigra with an α-synuclein reactive Lewy body. f: The section stained for iron
shows prominent iron accumulation in the deep grey matter nuclei and at the cortico/subcortical border; some increased iron reactivity is seen within
the periventricular demyelinated lesions: g: Subpial cortical lesion in the insular cortex (Fig. 1a) with selective loss of myelin in the cortex; h, i: The
subpial lesions shows an actively demyelinating edge with high density of activated microglia (Iba-1, Fig. 1h), expressing the phagocytosis associated
marker CD68 (Fig. 1i). j, k: In the meninges, covering the active lesion, inflammatory infiltrates are seen, composed or perivascular T-cells (CD3, Fig. 1j)
and B-cells (CD20, Fig. 1k); l: The active lesion edge of the cortical lesions contains numerous macrophages with PLP reactive myelin degradation
products; m: Activated microglia and macrophages at the lesions edge express NADPH oxidase
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also used to determine the number of axons with
disturbance of axonal transport, reflected by the positiv-
ity for amyloid precursor protein, and for the presence
of axons with terminal end bulbs.
Results
Basic pathology of human autoimmune encephalitis
(HAE)
Analysis of the entire brain hemispheric sections showed
large periventricular inflammatory demyelinating lesions
with partial preservation of axons (Fig. 1). Peri-venous
finger like extensions of the lesions into the adjacent
white matter were prominent (Dawson Fingers, [11]). In
addition, numerous small peri-venous areas of demyelin-
ation were seen in the entire cerebral white matter.
Demyelination was also present in the cortex and in
deep grey matter nuclei as previously described in MS.
[30] In the cortex small intra-cortical and larger subpial
lesions were visible. Grey matter demyelination was par-
ticularly pronounced in the hippocampus (Fig. 1a and b).
The vast majority of the lesions showed active demyelin-
ation at the edges, characterized by a dense rim of
activated macrophages and the presence of early myelin
degradation products within macrophages and microglia
Fig. 1c, d, Fig. 2a). Demyelination was associated with
complete loss of oligodendrocytes (Fig. 1d) and remyelina-
tion was absent. TUNEL staining revealed some cells with
DNA fragmentation with a morphological appearance of
necrosis at the edge and in the center of the lesions.
Nuclear accumulation of apoptosis inducing factor, a
hallmark of cell degeneration in Pattern III lesions of mul-
tiple sclerosis [56] was not found. Profound microglia
Table 1 Antibodies used for immunocytochemistry
Primary antibody Antibody type Target Source Staining
PLP Mouse (mAB) Proteolipid protein MCA8394; AbD Serotec 1:1000; E
MAG Mouse (mAB) Myelin-associated glycoprotein ab89780; Abcam 1:1000; E
MOG Mouse /mAB) Myelin oligodendrocyte
glycoprotein
8-18C5; C. Lininton, Cardiff, UK 1:1000; C
GFAP Mouse (mAB) Glial fibrillary acid protein 0410080; ThermoSc 1:200; E
pNF Mouse (mAB) Phosphorylated Neurofilament Affinity, SMI31,NA1219, Exeter, UK 1:20000; E
APP Mouse (mAB) Amyloid precursor protein MAB348; Chemicon, Temecula,
CA, USA
1:1000; C





CD68 Mouse (mAB) Cluster of Differentiation 68 M0814; Dako 1:100; E
p22phox Rabbit (pAB) NADPH oxidase Sc-20781; Santa Cruz, 1:100; C
CD3 Rabbit (mAB) T-cells RM-9107-S; Neomarkers, Fremont,
CA, USA
1:2000; E
CD4 Mouse (mAB) CD4 T-cells ACRIS, 1F6; DM-119-05, San Diego,
CA, USA
1:1000; E
CD8 Mouse (mAB) CD8 T-cells M7103; Dako, Glostrup, Denmark 1:250; E
CD20 Mouse (mAB) B-cells MS-340-S; Neomarkers, Fremont,
CA, USA
1:100; E
CD138 Mouse (nAB) Plasma Cells Serotec, MCA 681H; UK 1:500; E
GranB Mouse (mAB) Granzyme B MS-1157-S; Neomarkers, Fremont,
CA, USA
1:1000; E
IgG Rabbit (pAB) Imunoglobulin G A0423, DAKO, Glostrup, DK 1:400; Prot.
IgA Rabbit (pAB) Immunoglobulin A A042, DAKO, Glostrup, DK 1:2000; Prot.
IgM Rabbit (pAB) Immunoglobulin M A426; DAKO, Glostrup, DK 1:400; Prot
C9neo Rabbit (pAB) Compement C9neo antigen P. Morgan; Cardiff, UK 1:2000; Prot
PCNA Mouse (mAB) Proliferating cell nuclear antigen M0879, DAKO, Glostrup, DK 1:10000; C
E06 Mouse (mAB) Oxidized phospholipids Avantilipids; 330001S, Alabaster, AL, USA 10μg/ml; none
α-Syn Mouse (mAB) α-Synuclein Aj.ROBOSCREEN, mab 5G4 1:1000; C
AT8 Mouse (mAB) Phosphorylated tau-protein (PHF) Immunogenetics, Ghent, Belgium 1:2000; C
AIF Rabbit (pAB) Apoptosis inducing factor Milipore, AB16501; Temecula, CA 1:250; C
mAB monoclonal antibody, pAB polyclonal antibody, C citrate buffer pH 6, E ethylenediaminetetraacetic acid buffer pH 9.0, prot Protease XXIV; 0.03 %, 15 min
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activation was also seen in the peri-plaque white matter
(Fig. 2a) and clusters of activated microglia (so called
microglia nodules, [41]) were abundant (Fig. 2b). Staining
for neurofilament revealed only a moderate reduction of
axons within the demyelinated lesions (Figs. 1e, 2e) in
comparison to the adjacent normal appearing white mat-
ter (Fig. 2d). The reduction of axonal density was 23 % at
the lesion edges and 34 % in the lesion center. However,
axonal spheroids and end bulbs (Fig. 2e) reactive for
amyloid precursor protein (APP, [13]) were numerous
in particular at the active edge of the lesions (Fig. 2f ).
At the lesion edge 32 % of the axons showed accumula-
tion of APP, but only 12 % revealed the presence of
axonal end bulbs as an indicator for axonal transection.
Highly activated “protoplasmic” astrocytes were
dispersed at sites of active demyelination and in the
peri-plaque white matter (Fig. 2g,h), and some of them
contained multiple nuclei or nuclear fragments
(Creutzfeldt Peters cells; Fig. 2h insert). Fibrillary astro-
cytic gliosis was seen in the inactive lesion center
(Fig. 2i). Active demyelination was associated with de-
position of activated complement (C9neo antigen;
Fig. 2c) in all lesions with initial stages of myelin
destruction. This was associated with dressing of mye-
linated fibers by immunoglobulin (IgM; Fig. 3l).
Actively demyelinating lesions were also seen in the
cortex (Fig. 1a). Fig. 1g shows an active subpial lesion in
the insular cortex. Active myelin destruction was
associated with activated microglia (Fig. 1h), containing
myelin degradation products (Fig. 1l) and expressing the
phagocytosis associated marker CD68 (Fig. 1i) and
NADPH oxidase (Fig. 1m). Active cortical demyelination
was topographically related to meningeal inflammation,
consistent of CD3 positive T-cells (Fig. 1j) and CD20
positive B-cells (Fig. 1k). However, no deposition of acti-
vated complement was seen in active cortical lesions at
the site of active demyelination, as described before in
MS. [9].
Overall these data show, that the lesions in HAE
reflect all pathological hallmarks seen in classical MS,
following a pattern of demyelination, which is associated
with antibody and complement deposition (Pattern II,
[36]). Pattern III demyelination, defined by loss of
myelin associated glycoprotein, distal oligodendrogliopa-
thy, oligodendrocyte apoptosis and a concentric type of
demyelination [1] were not encountered in this patient.
Fig. 2 Demyelination and gliosis in active white matter lesions: a: Activity at the edge of the lesion is associated with densely packed activated
macrophages and microglia, expressing NADPH oxidase; profound activation of microglia is also seen in the peri-plaque white matter; the insert show
the presence of luxol fast blue positive myelin degradation products within macrophages; b: In the peri-plaque white matter numerous microglia
nodules are present, expressing NADPH oxidase; c: At the active lesion edge profound deposition of activated complement (C9neo antigen) is visible,
which appears to dress degenerating myelin (insert); d, e: Staining for phosphorylated neurofilament shows reduction of axonal density within the lesion
(e) in comparison to the peri-plaque white matter (d); axonal spheroids or end bulbs are mainly present at the lesion edge (e, insert); f: dystrophic axons at
the lesion edge show accumulation of amyloid precursor protein (APP) as a sign of disturbed axonal transport; g, h: Profound protoplasmic
astrocytic gliosis is seen in sections stained for glial fibrillary acidic protein (GFAP); some of the astrocytes resemble the pathological changes
of Creutzfeldt Peters cells (insert in h). i: Fibrillary astrocytic gliosis is seen in the demyelinated lesion center
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Inflammatory reaction
The demyelinating pathology, described above occurred
on a background of a very severe inflammatory reaction
(Fig. 3). Numerous very large inflammatory infiltrates
were present within the lesions, while inflammation was
sparse in the normal appearing white matter and virtu-
ally absent in the cortex. However, inflammation was
present in the leptomeninges in close proximity to cor-
tical demyelinated lesions (Fig. 1a, j, k). The inflamma-
tory infiltrates contained high numbers of CD3+ T-cells
(Fig. 3 b) and a very similar number of CD8+ cells
(Fig. 3d). In contrast, CD4+ T-cells were exceptionally
rare. As an example, in the very large inflammatory infil-
trate, depicted in Fig. 3c, only one single CD4+ T-cell
was found (asterisk and insert). By far, however, the most
numerous components of the inflammatory infiltrates
were CD20+ B-cells, which outnumbered T-cells by a
factor of 3 to 4 (Fig. 3e). In addition, CD138 positive
plasma cells were seen in separated regions of the infil-
trates (Fig. 3f ), which mainly contained IgM (Fig. 3i) but
only occasionally IgG (Fig. 3g) or IgA (Fig. 3h). The large
inflammatory infiltrates in the perivascular spaces and
Fig. 3 Patterns of inflammation in HAE: a: Within the demyelinating lesions a very pronounced inflammatory reaction is seen, characterized by
the presence of numerous densely packed perivascular inflammatory cuffs; b, c, d: The inflammatory cuffs contain high numbers of CD3+ and
CD8+, but only exceptionally CD4+ T-cells; the insert in c shows the single CD4+ T-cells within the entire inflammatory cuff at high magnification;
CD3+ and CD8+ T-cells are also seen diffusely infiltrating the lesion parenchym (d, d). e: CD20+ B-cells are the dominant leukocyte population
within the perivascular cuffs; f: In addition to T-cells and B-cells the inflammatory infiltrates also contain CD138+ plasma cells, shown at high
magnification in the insert; note that the T-cells, B-cells and plasma cells are located in different sub-regions of the cuff, similar to that seen in
lymph follicle like structures, present in chronic inflammatory conditions; g-i: The majority of plasma cells within the infiltrates contain IgM (i),
while the number of IgG (g) and IgA (h) positive plasma cells is low; j: IgM containing plasma cells are also diffusely dispersed in the lesion
parenchyma; k: at the lesion edge IgM is seen associated with myelinated fibers; l-n: Double staining of sections with the proliferation marker
PCNA and leukocyte markers shows local proliferation of CD8+ T-cells and CD20+ B-cells in perivascular cuffs, while in the parenchyma of the
lesion only proliferating CD8+ T-cells are seen
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meninges showed clear separation of T-cell, B-cell and
plasma cell dominated regions in a pattern, similar to
that described in lymph-follicle like inflammatory aggre-
gates in MS. [47] Diffuse inflammatory infiltrates within
the lesion parenchyma mainly consisted of CD8+ T-cells
(Fig. 3d) and IgM+ plasma cells (Fig. 3j). At the lesions
edges, dressing of myelin sheaths with IgM was noted
(Fig. 3k). Proliferation of leukocytes was determined by
the expression of the proliferation marker PCNA in T-
cells and B-cells. Double stained cells were CD8+ cells in
perivascular cuffs and in diffuse infiltrates in the paren-
chyma (Fig. 3l, m) and CD20+ perivascular cells (Fig. 3n).
Quantitative data on the percentage of different leukocyte
subsets in perivascular cuffs are provided in Table 2.
The unusually high B-cell component within the le-
sions may indicate Epstein Barr Virus infection of these
cells, as suggested before to occur in MS lesions [48]. To
address this question we performed in situ hybridization
for EBV/EBER using an autopsy case with a cerebral
EBV related lymphoma as a positive control, which
showed prominent EBV EBER signal in the nucleus of
malignant B-cells (Fig. 4k). In contrast, no single EBER
positive cell was found in the HAE case (Fig. 4l). It is
unlikely that the absence of EBER reactivity within our
case of HAE is due to technical reasons, since EBER in
situ hybridization provides consistent results in human
autopsy brain tissue [32] and the quality of tissue preser-
vation, including mRNA preservation, in our case of
HAE was better compared to that seen in other routine
autopsy tissues (see in situ hybridization for proteolipid
protein mRNA shown above).
Oxidative injury in neurons and glia
Oxidative injury has recently been identified as a major
tissue alteration associated with demyelination and neu-
rodegeneration in MS lesions [14] and it was suggested
that oxidative injury may be amplified in the presence of
iron in the aging human brain and its liberation in active
MS lesions [22]. In line with the age of the patient pro-
found iron accumulation was found in the brain (Fig. 1f ),
which was most prominent in the basal ganglia and the
substantia nigra, followed by the cortico/subcortical
border zone. Iron reactivity was mainly seen in myelin
and oligodendrocytes as described before ([20]; Fig. 4a,
c). Active areas of the white matter lesions contained a
low iron load, but iron accumulated in macrophages in
the lesion center (Fig. 4a). In contrast, massive iron load
was present in lesions, which affected the basal ganglia
(Fig. 4b). As described before in MS, iron was lost from
myelin and oligodendrocytes and accumulated in macro-
phages and microglia in these lesions (Fig. 4d). In
addition, granular iron reactivity was present in the
extracellular space, as described before in MS lesions
[22]. Oxidative injury, reflected by the cytoplasmic accu-
mulation of oxidized lipids in white matter lesions and
the cortex was low in comparison to that seen in acute
MS cases with Pattern III pathology or in the lesions of
patients with progressive MS. [14, 21] However, in the
lesions affecting areas with high iron content in the basal
ganglia accumulation of oxidized phospholipids was seen
in neurons, dystrophic axons and glia (Fig. 4f-j).
Pathological changes in the substantia nigra
Consistent with the clinical presentation, moderate
changes of Parkinson’s disease were seen in the substan-
tia nigra, characterized by a mild reduction of pigmented
cells and the presence of few cells with Lewy bodies, re-
active for α-synuclein (Fig. 1e, insert). No Lewy bodies
were seen in the hippocampus or cortex (Braak&Braak
stage III of Parkinson´s disease; brainstem predominant
Lewy body type pathology according to McKeith
criteria). Despite the presence of neurodegeneration the
substantia nigra was not targeted by the inflammatory or
demyelinating process.
Comparison of HAE with MS and EAE in rodents and
primates
Similarities and differences between the case of HAE
and MS or animals models of EAE are summarized in
Table 3. Most pathological hallmarks, considered to be
specific for MS, were shared between HAE and MS. One
major difference was that none of the lesions showed a
demyelinating pattern, characterized by distal oligoden-
drogliopathy and oligodendroglia apoptosis (pattern III;
[34]). This pattern of demyelination seems to represent
an extreme example of tissue injury mediated by oxida-
tive and mitochondrial injury [14, 38] and its absence in
this case is in line with the relatively mild oxidative in-
jury, which was largely restricted to areas with high iron
content and liberation into the lesions.
Table 2 Percentage of specific leulocyte subsets of total
perivascular cells in inflammatory cuffs in HAE
Leukocyte Percentage of









% proliferating CD8+ cells 2.3
% proliferating CD20+ cells 3.5
Counts are based on a total of 400 cells / cuff / marker; for enumerating CD4+
T-cells a total of 3.000 cells / cuff were analysed
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A major quantitative difference was also seen in the
composition of inflammatory infiltrates. In the case de-
scribed here the infiltrates largely contained CD20+ B-
cells and CD8+ T-cells, while CD4+ lymphocytes were
virtually absent. In addition plasma cells were found,
which dominantly contained IgM. In MS inflammation
is dominated by CD8+ T-cells and the number of CD20
+ B-cells is much lower [16]. Furthermore, plasma cells
in MS lesions mainly produce IgG and in much lower
incidence IgA and IgM [12]. Also in MS CD4+ T-cells
are sparse.
For the comparison with animal models we focused on
the two extreme examples of the EAE spectrum, MOG
peptide induced chronic EAE in C57Bl6 mice, which is a
purely CD4+ T-cell mediated disease, which is most easy
to induce and most reproducible, and is, thus, preferen-
tially used in immunological studies of MS. [18] The
other is the chronic EAE model induced by recombinant
MOG in incomplete Freund’s adjuvant in marmoset
monkeys, which appears to be most close regarding gen-
etic background and method of sensitization to the case
described in this study, but is heterogeneous between
animals regarding clinical disease and severity of the
pathological alterations [27]. The pathology of marmoset
EAE revealed an inflammatory demyelinating disease in
many essential criteria similar to MS and HAE,
Fig. 4 Iron deposition and oxidative injury in HAE: a: Related to white matter lesions a moderate iron deposition is seen in the peri-plaque white matter
(left side), while very little iron is present in the active edge of the lesion; in the lesion center numerous iron containing macrophages are present (right
side); b: In contrast, in lesions in the basal ganglia massive iron deposition is present in the peri-plaque grey matter and a high content of iron containing
macrophages and microglia (left side) are seen within the lesion (right side); c: Higher magnification shows the presence of iron in oligodendrocytes and
myelin in the normal appearing white matter; d, e: in basal ganglia lesions iron is mainly seen in microglia and macrophages (d), but is also present in the
form of small extracellular iron granules (e); f-j: Oxidative injury is visualized by the cytoplasmic accumulation of oxidized phospholipids (E06 reactivity); it is
mainly seen in basal ganglia lesions in neurons (f, g) in dystrophic axons (i) and in astrocytes and oligodendrocytes (j); as described before in MS lesions
E06 reactivity is present diffusely within the cytoplasm of neurons and oligodendrocytes, while in astrocytes (j) it is sequestered in cytoplasmic granules,
possibly reflecting autophagy of damaged cell components; only very few cortical neurons show cytoplasmic accumulation of oxidized phospholipids at
sites of lesion activity (h). k, l: Cells with nuclear EBV / EBER reactivity are present in high numbers in a control case of EBV positive cerebral lymphoma (k),
while no single cell with EBER reactivity is seen in the inflammatory cuffs or the lesion parenchyma in the HAE case
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following a pattern of demyelination, that suggest in-
volvement of demyelinating antibodies (Pattern II; [36]).
There were, however some differences in astrocyte and
microglia reaction and the inflammatory reaction in
marmosets is dominated by T-cells, while the B-cell
component is less pronounced and IgM producing
plasma cells are sparse. Pathological alterations, related
to iron deposition in the central nervous system and to
oxidative injury were sparse or absent (Table 3).
In contrast to EAE in humans and primates, the lesions
in chronic mouse models after active sensitization with
MOG35–55, are fundamentally different in many respects.
Primary demyelination is sparse and larger focal lesions
are mainly due to inflammatory neurodegeneration with
secondary demyelination. Inflammation is dominated by
CD4+ T-cells and the contribution of other leukocyte
subsets is sparse. Furthermore, macrophage and microglia
reaction are profoundly different between this model and
the human condition [44]. Finally, the extensive oxidative
injury seen in the brain of patients with progressive MS,
which is associated with slow expansion of pre-existing
lesions and diffuse damage of the grey and white matter
was neither reproduced in marmoset or mouse EAE
models, nor in our case of HAE.
However, comparing EAE models with MS one has to
consider that numerous different EAE models have been
described, and the pathological alterations in the brain
and spinal cord cover a broad spectrum, which resides
between the two extremes, elaborated above in this
study [34, 40, 42, 49, 52].
Discussion
We show here that the vast majority of putative disease
specific pathological alterations of MS are well repro-
duced in a patient with brain autoimmune disease
induced by active sensitization with brain cells. However,
inflammatory demyelination, as shown in this case, is
not always a feature of autoimmune-disease following
sensitization with brain antigens. In contrast, acute de-
myelinating polyradiculoneuritis and acute disseminated
encephalomyelitis are more common than MS like in-
flammatory demyelination [2, 50]. In our case we found
no clinical evidence that the patient suffered from MS
prior to sensitization with brain antigens. Furthermore,
all lesions in this patient presented with a similar stage
of activity with active demyelination at the edge and an
inactive lesion center, which was still diffusely infiltrated
with macrophages. No separate inactive or remyelinated
lesions were present in the entire brain. However, one
can argue that MS like pathology is only seen in patients,
who have a similar genetic predisposition compared to
MS patients [20, 25], or who have been exposed to similar
environmental challenges. In this case auto-sensitization
with brain tissue would provide a trigger of the disease in
a susceptible individual. As an example, EBV infection is
associated with MS in epidemiological studies [3]. Pres-
ence of EBV infected B-cells in the MS brain has been
described [48], but this observation could not be con-
firmed in other studies [32, 39, 58]. Despite the very high
number of B-cells within the lesions in our case, we did
not find a single EBV / EBER positive cell. If EBV expos-
ure may have been involved in the development of the dis-
ease, it would have been in the peripheral immune system
and not in the brain.
Alternatively, the mode of sensitization may have
played a role in the induction of the demyelinating dis-
ease phenotype. A common feature of all patients, who
developed HAE with widespread MS like primary de-
myelination was the immunization with native or phenol
treated brain tissue in saline in the absence of adjuvants
[28], which was applied by multiple injections over a
prolonged time period [46, 54]. This was reproduced
experimentally with a similar sensitization protocol in
the earliest studies on EAE in monkeys [42]. With the
introduction of Freund’s adjuvant in the immunization
process the development of brain autoimmune disease
was enhanced, resulting in reproducible disease models
[29] by forcing mainly CD4+ T-cell driven inflammation
[6]. Thus, the difference in the inflammatory response
and the extent of demyelination between HAE, as shown
in our current study, and classical EAE models may in
part be related to the lack of immune stimulation by
Freund’s adjuvant.
The nearly complete absence of CD4+ T-cells in the
inflammatory infiltrates in the case described here indi-
cates that other inflammatory cells, such as CD8+ T-cells
or B-lymphocytes are important in driving inflammation
and tissue injury in demyelinating HAE, while a disease
phenotype of ADEM or polyradiculoneuritis may mainly
be driven by a (CD4+) T-cell response, as suggested by
its similarity to classical EAE models [2, 50]. However,
ADEM pathogenesis may be heterogeneous, including
also cases with additional presence of potentially demye-
linating anti-MOG antibodies [57]. In multiple sclerosis
lesions the T-cell infiltration of the brain tissue is domi-
nated by CD8+ T-cells and these cells show preferential
clonal expansion [4, 15]. In addition, CD20+ B-cells and
plasma cells are present in variable numbers [12, 16].
Most importantly, therapies, which selectively target
CD4+ T-cell responses, have been ineffective (anti CD4:
[55]; Ustekinumab: [45]), while therapies which target T-
cell and B-cell infiltration into the CNS (Fingolimod:
[10], Alemtuzumab: [53], Natalizumab: [35]) or which
selectively eliminate circulating B-cells (Rituximab: [23])
are effective.
Regarding mechanisms of demyelination we found im-
munoglobulin (mainly IgM) and C9neo deposition at
sites of active myelin destruction and tissue damage,
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Table 3 Comparison of HAE with MS and EAE Models
MS Pathology AcuteMS Progr. MS Case HAE Marmoset MOG EAE Mouse MOG EAE
Demyelination
DM Plaques yes yes yes yes yesa
Perivenous / Confluent yes yes yes yes yes
Periventricular yes yes yes yes no
Slowly expanding lesions no yes no no no
Dawson Fingers yes yes yes yes no
Leukocortical Lesions yes yes yes yes no
Intractortical Lesions yes yes yes yes no
Subpial lesions few many few yes no
Shadow plaques few var no yes no
Pattern II DM
C9neo Deposition var few yes yes no
Ig Deposition var var yes yes no
Macrophage association yes yes yes yes yes
Pattern III DM
Pre-phagocytic Lesions var few no no no
Oligodendrocyte Apoptosis var var no no no
Concentric DM Pattern var rare no no no
Axonal / Neuronal Pathology
Relative axonal pres. yes yes yes yes no
Acute injury in act. lesions yes yes yes few yes
Diffuse axonal Injury few mod few few few
Retrograde Neurodegeneration few yes few n.d. yes
Astrocyte Pathology
Protoplasmic gliosis in active lesions yes yes yes mild yes
Creutzfeldt Peters Cells many few many no no
Fibrillary Gliosis in inactive lesions yes yes yes yes yes
Aquaporin 4 loss Var (Pat III) no no n.d. no
Inflammation
CD3 many many many many many
CD4 few few single n.d. many
CD8 many many many n.d. few
CD20 mod mod massive mod few
Plasma Cells mod mod mod mod few
Follicle like structures var var yes yes no
IgG PC many many few mod n.d.
IgA PC few few few n.d. n.d.
IgM PC few few many few n.d.
PCNA CD8 yes yes yes n.d. n.d.
PCNA CD20 yes yes yes n.d. n.d.
Microglia / Macrophages
Iba1 (active lesions) many many many many many
CD68 (active lesions) many many many n.d. many
NADPH oxidase microglia many many many n.d. no
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consisting with a pattern II demyelination according to
Lucchinetti et al. [36]. The presence of lipid-specific IgM
in the cerebrospinal fluid has been identified as a
negative prognostic marker in MS patients [51] and co-
localization of IgM with activated complement on axons
and oligodendrocytes has been shown before in MS [43].
Prominent somatic hyper-mutation of IgM chains within
the cerebrospinal fluid of MS patients suggests antigen
specific clonal expansion of IgM producing B-cells [5].
In contrast, we did not find any indications for a pat-
tern III type of demyelination in active lesions. Pattern
III demyelination is mainly associated with massive oxi-
dative and mitochondrial injury [1, 14, 37] and in line
with this observation, oxidative injury, reflected by the
accumulation of oxidized lipids in myelin and oligoden-
drocytes in active white matter lesions was not seen in
our case. We found, however, oxidative injury in
neurons and glia in demyelinating lesions in the basal
ganglia, associated with high tissue iron content and
extracellular iron liberation at sites of active demyelin-
ation. These data indicate that iron accumulation in the
aging human brain and its liberation from myelin and
oligodendrocyte stores may amplify oxidative injury in
inflammatory demyelinating lesions [22].
Conclusion
In conclusion, our study shows that a disease, which ful-
fills all pathological criteria for a pathological diagnosis
of MS, can be induced by direct auto-immunization of
humans with brain tissue. However, we also show that
the detailed immunopathology of demyelinating HAE is
different in many respects from that seen in classical
EAE models in primates and rodents, that CD8+ T-cells,
CD20+ B-cells and IgM producing plasma cells may play
a decisive role in the induction of the disease and that
this may be similar in MS patients. A major limitation of
our current study is that it is restricted to the analysis of
a single case. A basically similar pathology of inflamma-
tory demyelination has previously been observed in a
series of patients treated with the rabies semple vaccine
[54]. We tried to retrieve archival autopsy material from
these cases for detailed immunopathological analysis, but
unfortunately we were informed that the respective mater-
ial is no longer available. Most importantly, however, auto-
immune encephalomyelitis in humans is a self-limiting
disease. When patients survive the neuroparalytic disease
after terminating rabies vaccination the patients recover
without evidence for chronic (progressive) disease [50].
What drives chronic and progressive disease in multiple
sclerosis remains unresolved.
Competing interest
None of the authors have any competing interests in the manuscript.
Authors’ contributions
RH and HL analyzed and interpreted the neuropathology on this case in
relation to other MS cases; they wrote and finally corrected the manuscript.
ML provided excellent technical support in immunocytochemistry and in
handling the large sections fo hemispheric tissue blocks. JB provided the
data on different EAE models togerther with HL.
Acknowledgements
The study was funded by the Austrian Science Fund (FWF, Project I 2114 –
MELTRA-BBB). We thank Ulrike Köck for expert technical assistance.
Author details
1Institute of Neurology, Medical University of Vienna, Vienna, Austria. 2Center
for Brain Research, Medical University of Vienna, Vienna, Austria.
Received: 20 November 2015 Accepted: 20 November 2015
Table 3 Comparison of HAE with MS and EAE Models (Continued)
Microglia nodules many mod many few no
Diffuse activation NAWM/GM mod massive mod no mod
Iron Related Pathology
Iron accumulation in NAWM/GM Age related Age related Profound (age) no no
Iron loss in lesions yes yes yes no no
Extracellular iron yes yes yes no no
Uptake in Macrophages / MG yes yes yes few no
Iron loss in PPWM yes yes no no no
Oxidative Injury
Ox Lipids OG and Myelin yes yes few (iron) no no
Ox lipids neurons yes yes few (iron) no no
EBV
EBER positive B-cells no no no n.d. n.d.
Acute MS Marburg type of acute MS, Progr. MS primary or secondary progressive MS, Case HAE human autoimmune encephalitis, described in this study, Marmoset
MOG EAE chronic EAE induced in marmosets by active sensitization with recombinant myelin oligodendrocyte glycoprotein in incomplete Freund’s adjuvant,
Mouse MOG EAE chronic EAE in C57Bl6 mice induced by active sensitization with MOG35–55 peptide
Yesa: white matter lesions in chronic mouse EAE are mainly due to massive axonal destruction and secondary demyelination
Mod moderate, mild mild, few(iron) only few cells in lesions with high iron content
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